Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
14
Added to
17
Trimmed
9
Exited
16
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $16.65B across 113 positions in their Q4 2022 SEC 13F filing (period ending 2022-12-31). The top 10 positions account for 87.0% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | $6.03B | 36.21% | - |
| 2 | INCYIncyte Corporation | $2.90B | 17.44% | +0.0% |
| 3 | ONCBeiGene, Ltd. | $2.57B | 15.41% | - |
| 4 | BMRNBioMarin Pharmaceutical Inc. | $788.64M | 4.74% | - |
| 5 | ACADACADIA Pharmaceuticals Inc. | $667.42M | 4.01% | - |
| 6 | ASNDUSDAscendis Pharma A/S | $605.14M | 3.63% | +2.1% |
| 7 | MDGLMadrigal Pharmaceuticals, Inc. | $448.47M | 2.69% | +3.1% |
| 8 | RYTMRhythm Pharmaceuticals, Inc. | $185.05M | 1.11% | +4.8% |
| 9 | BCRXBioCryst Pharmaceuticals, Inc. | $145.92M | 0.88% | - |
| 10 | IMCRImmunocore Holdings plc | $143.86M | 0.86% | - |
| Stock | Value | Shares |
|---|---|---|
| SWTXUSDSpringWorks Therapeutics, Inc. | $39.76M | 1,528,538 |
| PRMEPrime Medicine, Inc. | $19.11M | 1,028,466 |
| SPRYARS Pharmaceuticals, Inc. | $17.12M | 2,006,451 |
| ZYMEZymeworks Inc. | $13.43M | 1,708,472 |
| RNAGBPAvidity Biosciences, Inc. | $9.65M | 434,782 |
| SMMTSummit Therapeutics Inc. | $8.50M | 2,000,000 |
| CMPXCompass Therapeutics, Inc. | $7.83M | 1,557,630 |
| BHVNBiohaven Ltd. | $6.61M | 476,190 |
| ROIVRoivant Sciences Ltd. | $5.73M | 716,653 |
| PRAXPraxis Precision Medicines, Inc. | $4.36M | 1,830,315 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.